Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16800 | 1.00 | CTSK (0.53) | CTSKCTSSAAK1NFKB1NFKB2 | |
| SCHEMBL2199572 | 1.00 | CTSK (0.53) | CTSKCTSSAAK1NFKB1NFKB2 | |
| SCHEMBL30557041 | 0.92 | CTSK (0.48) | CTSKCTSSAAK1NFKB1NFKB2 | |
| SCHEMBL14151599 | 0.90 | CTSS (0.63) | CTSKCTSSAAK1NFKB1NFKB2 | |
| SCHEMBL6078092 | 0.90 | CTSS (0.63) | CTSKCTSSAAK1NFKB1NFKB2 | |
| SCHEMBL7084925 | 0.90 | CTSS (0.63) | CTSKCTSSAAK1NFKB1NFKB2 | |
| SCHEMBL16773 | 0.88 | CTSS (0.57) | CTSKCTSSAAK1KMT2AHDAC4 | |
| SCHEMBL16774 | 0.88 | CTSS (0.57) | CTSKCTSSAAK1KMT2AHDAC4 | |
| SCHEMBL19385461 | 0.87 | CTSK (0.63) | CTSKCTSSAAK1NFKB1NFKB2 | |
| SCHEMBL29414317 | 0.87 | CTSK (0.60) | CTSKCTSSAAK1NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165452-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389552-B2 | (S)-6-(2-(4-(cyclobutylsulfonyl)-1H-imidazol-1-yl)-3-cyclopentylpropanamido)nicotinic acid useful as a glucokinase activator | PFIZER INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329920-B2 | Substituted imidazoles useful for treating type II diabetes | PFIZER INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120225910-A1 | Substituted Heteroaryls | PFIZER INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-7977367-B2 | Substituted imidazole propanamide glucokinase activators | PFIZER INC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977367-B2 | Substituted imidazole propanamide glucokinase activators | PFIZER INC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977367-B2 | Substituted imidazole propanamide glucokinase activators | PFIZER INC (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110130365-A1 | Fluorinated Heteroaryls | BENBOW JOHN W | 2011-06-02 | — | — | US | disclosed |
| US-20110130365-A1 | Fluorinated Heteroaryls | BENBOW JOHN W | 2011-06-02 | — | — | US | disclosed |
| WO-2010084428-A1 | SUBSTITUTED PYRAZINONE AMIDES | PFIZER INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100184777-A1 | Substituted Pyrazinone Amides | PFIZER INC | 2010-07-22 | — | — | US | disclosed |
| US-20100184777-A1 | Substituted Pyrazinone Amides | PFIZER INC | 2010-07-22 | — | — | US | disclosed |
| US-20100063063-A1 | Substituted Heteroaryls | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
| US-20100063063-A1 | Substituted Heteroaryls | PFIZER INC | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184777-A1 | Substituted Pyrazinone Amides | GCK, GCKR, PDK2 | CTSK 259/4885CTSS 1574/4885AAK1 108/4885 |
| US-20110130365-A1 | Fluorinated Heteroaryls | GCKR, GALK1, GCK | CTSK 659/4885CTSS 1972/4885AAK1 596/4885 |
| US-20120225910-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | CTSK 296/4885CTSS 905/4885AAK1 173/4885 |
| US-20100063063-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | CTSK 295/4885CTSS 961/4885AAK1 171/4885 |
| US-20130165452-A1 | Substituted Heteroaryls | GCKR, GCK, GALK1 | CTSK 295/4885CTSS 961/4885AAK1 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.